Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revolution Medicines, Inc.

https://www.revmed.com/

Latest From Revolution Medicines, Inc.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

ESMO 23: Analysts Keep Faith In Revolution’s Multi-RAS Drug Despite Investor Fright

Revolution Medicines is aiming to go beyond Amgen and Mirati’s first-generation drugs with a multi-RAS targeting therapy - and despite a market sell-off after ESMO, analysts think the company think it is still on track.

Clinical Trials Companies

FDA Postmarket Guidance Hammers Home Positions On Foreign Trials, Real-World Evidence

US agency emphasizes and formalizes long-standing viewpoints on hot topics including accelerated approval in a new guidance on postmarket study diversity.

Post Market Regulation & Studies Guidance Documents

Chinese PD-1s Eye US Approvals Despite Lack Of Action Dates

Although Novartis/BeiGene’s tislelizumab and Coherus /Junshi’s toripalimab have not received a new Prescription Drug User Fee Act (PDUFA) decision date for their biologics license applications in the US, the companies remain hopeful that potential approvals will be granted in the third quarter at the earliest.

China ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Warp Drive Bio, Inc.
UsernamePublicRestriction

Register